

研究成果の刊行に関する一覧表

Yamagishi A, Morita T, Miyashita M, et al	Providing palliative care: the views and exposure of community general practitioners and district nurses in Japan.	J Pain Symptom Manage	43(1)	59-67	2012
Deno M, Miyashita M, et al	The relationships between complicated grief, depression, and alexithymia with the seriousness of complicated grief in Japanese general population.	J Affect Disord	135	122-7	2011
Kinoshita S, Miyashita M.	Development of a scale for "difficulties felt by ICU nurses providing end-of-life care" (DFINE): A survey study.	Intensive & Critical Care Nursing	27(4)	202-10	2011
Hirai K, Kudo T, Akiyama M, Matoba M, Shiozaki M, Yamaki T, Yamagishi A, Miyashita M, et al	Public Awareness, Knowledge of Availability, and Readiness for Cancer Palliative Care Services: A Population-Based Survey across Four Regions in Japan.	J Palliat Med	14(8)	918-22	2011
Yoshida S, Hirai K, Morita T, Shiozaki M, Miyashita M, et al	Experience of families of Japanese patients with cancer for prognostic disclosure.	J Pain Symptom Manage	41(3)	594-603	2011

書籍（日本語）

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
佐々木寛	広汎子宮全摘術（神経温存）	落合和徳 青木大輔	婦人科がん 低侵襲手術	メディカル レビュー 社	東京	2012	20-23
	准広汎子宮全摘術（子宮動脈からの尿管枝を温存する術式）						30-33
	婦人科癌手術におけるリンパ浮腫の予防の試み						62-65

## 研究成果の刊行に関する一覧表

雑誌（日本語）

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
井本 滋, 菅間 博, 和田徳昭	「悪性腫瘍の術中病理診断を効果的に活用する - どこを検索すべきか、どう対応すべきか -」	臨床外科	66	454-6	2011
井本 滋	ラジオアイソトープ (RI) 法を用いた乳癌センチネルリンパ節生検手技	手術	65	409-12	2011
井本 滋	術前化学療法とセンチネルリンパ節生検	臨床外科	66	882-5	2011
井本 滋	「進歩する癌転移診断 - 外科臨床はどう変わるのか」乳癌	臨床外科	66	1312-6	2011
伊東 大樹, 井本 滋	治療検査 (治療モニタリングと腫瘍マーカー)	治療	93	1242-5	2011
井本 滋	センチネルリンパ節生検について	治療	93	1074-6	2011
齋藤典男、杉藤正典、伊藤雅昭、小林昭広、西澤雄介、	下部直腸癌に対する周術期 (術前・術後) 化学放射線療法の有用性、大腸癌 - 最新の研究の動向 -、VIII. 大腸癌の治療戦略放射線療法、	日本臨床	69(3)	500-4	2011
西澤祐史、藤井誠志、齋藤典男、伊藤雅昭、杉藤正典、小林昭広、西澤雄介、中嶋健太郎、甲田貴丸、錦織英知、	ISR術前化学放射線療法における術後肛門機能に関する組織学的要因、	癌の臨床	56(8)	575-8	2011
甲田貴丸、伊藤雅昭、齋藤典男、杉藤正典、小林昭広、西澤雄介、西澤祐史、中嶋健太郎、	術前放射線化学療法のISR術後肛門機能へ与える影響、	癌の臨床	56(8)	579-84	2011
齋藤典男、杉藤正典、伊藤雅昭、小林昭広、西澤雄介、	直腸癌に対する低位前方切除、	手術	65(6)	905-12	2011
齋藤典男、伊藤雅昭、小林昭広、西澤雄介、杉藤正典、	直腸癌に対する肛門温存手術、	日外会誌	112(5)	318-24	2011
佐々木寛、佐々木徹、多田春江、飯田泰志、武石明精、	婦人科癌術後の下肢リンパ浮腫の危険要因と後腹膜大腿ソケイ部でのリンパ管静脈吻合術の有効性	日本マイクロサージャリー学会会誌	24-3	240-7	2011

研究成果の刊行に関する一覧表

高野浩邦, 河西十九三, 早田篤子, 立花美津子, 石塚康夫, 茂木真, 小竹譲, 生水真紀夫, 佐々木寛, 田中忠夫	子宮頸がん検診へのベセスダシステム2001導入による不適正検体の頻度の実際とその推移.	日本臨床細胞学会雑誌	50-3	158-62	2011
池田公史.	ソラフェニブの副作用対策(手足症候群・下痢・高血圧)	医学のあゆみ	236	711-5	2011
池田公史.	臨床で分子標的薬を使用する際のポイント 肝細胞癌	Prog.Med.	31	2607-13	2011
森田達也, 野末よし子, 花田芙蓉子, 宮下光令, 鈴木聡, 木下寛也, 白髭豊, 江口研二	地域対象の緩和ケアプログラムによる医療福祉従事者の自覚する変化: OPTIM-study.	Palliat Care Res	7巻1号	121-35	2012
山岸暁美, 森田達也, 古村和恵, 末田千恵, 白髭豊, 木下寛也, 秋月伸哉, 鈴木聡, 加藤雅志, 江口研二	地域のがん緩和ケアの課題と解決策の抽出OPTIM-Studyによる複数地域・多職種による評価	癌と化学療法(0385-0684)	38巻11号	1889-95	2011

DOI: 10.1002/cmdc.201100564

## Synthesis and Evaluation of Anticancer Natural Product Analogues Based on Angelmarin: Targeting the Tolerance towards Nutrient Deprivation

Jakob Magolan,<sup>[a]</sup> Nathan B. P. Adams,<sup>[a]</sup> Hiroko Onozuka,<sup>[b]</sup> Natasha L. Hungerford,<sup>[a]</sup> Hiroyasu Esumi,<sup>[b]</sup> and Mark J. Coster<sup>\*[a]</sup>


Rapidly growing solid tumours are often inherently hypovascular, thus exhibiting reduced oxygen and nutrient supply.<sup>[1–2]</sup> This has been well documented in pancreatic tumours.<sup>[3–5]</sup> Rather than impeding cancer progression, such poor metabolic conditions can contribute to genomic instability, impaired cellular repair, mutagenesis, and resistance to chemotherapy, thus worsening prognoses for patients.<sup>[6–9]</sup>

The therapeutic strategies of angiogenesis inhibition<sup>[10,11]</sup> and vascular targeting<sup>[12]</sup> endeavour to kill tumour cells by selectively depriving them of oxygen and nutrients. In this light, aggressive tumours that thrive despite being chronically hypoxic and nutrient-deprived present a serious therapeutic challenge. Despite considerable evidence of angiogenesis,<sup>[13–17]</sup> many pancreatic tumours remain hypovascular, hypoxic, and starved of nutrients while continuing to grow rapidly.

In 2000, Esumi and co-workers showed conclusively that certain pancreatic cancer cell lines, in contrast to other cancer cell lines and normal human fibroblasts, demonstrate an extraordinary capacity for survival in nutrient-deprived medium (NDM).<sup>[18]</sup> The specific biochemical mechanisms associated with starvation resistance, termed austerity, continue to be elucidated.<sup>[19]</sup>

Concurrently, a screening method for antiausterity activity has been developed,<sup>[20]</sup> and a number of small-molecule inhibitors of this process—antiausterity agents—have recently been identified.<sup>[19]</sup> Furthermore, three of these antiausterity agents have been shown *in vivo* to slow the growth of xenograft tumours of PANC-1, a human pancreatic carcinoma, epithelial-like cell line.<sup>[20–22]</sup> Subsequent to our recent comparative review of known antiausterity agents,<sup>[19]</sup> the first simplified natural product analogues with modest antiausterity activity have been described.<sup>[23,24]</sup>

During their extensive discovery efforts using antiausterity bioassay-guided fractionation of plant extracts,<sup>[25–33]</sup> Awale, Kadota and co-workers isolated (+)-angelmarin from *Angelica pubescens*, finding it to have preferential cytotoxicity (PC; see below for definition) towards PANC-1 cells in



NDM (24 hour incubation) at a concentration of 0.01  $\mu\text{g mL}^{-1}$  ( $\text{PC}_{100} = 26 \text{ nM}$ ), with no cytotoxicity in nutrient-rich medium.<sup>[25]</sup>

In 2009, we disclosed an enantioselective synthesis of (+)-angelmarin.<sup>[34]</sup> Total syntheses of this target compound have also been recently reported by Hamada<sup>[35]</sup> and Banwell.<sup>[36]</sup> Herein, we provide results of ongoing structure–activity relationship (SAR) investigations into this natural product, with the long-term aim to gain sufficient insight for the development of probes to study the mechanism of action and to elucidate the biological target(s) for antiausterity.

Our eight-step synthetic sequence afforded (+)-angelmarin in 37% overall yield and 75% enantiomeric excess (*ee*) from commercially available umbelliferone.<sup>[34]</sup> The racemate was also prepared in six steps in 48% overall yield, as shown in Scheme 1.<sup>[34]</sup> Allylation of umbelliferone, followed by Claisen rearrangement yielded **2**.<sup>[37]</sup> Cross metathesis of terminal olefin **2** and 2-methyl-2-butene in the presence of Grubbs' second-generation catalyst provided osthenol (**3**). Epoxidation with *meta*-chloroperoxybenzoic acid (*m*-CPBA) in the presence of potassium carbonate readily yielded *rac*-columbianetin (**4**). Treatment with 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) in refluxing toluene provided carboxylic acid **5**, which was converted to ( $\pm$ )-angelmarin (**6**) via a Doebner-Knoevanagel condensation, by heating the substrate in the presence of 4-hydroxybenzaldehyde and piperidine in pyridine (82% yield, over two steps).

The final step of this sequence was readily amenable to divergent analogue synthesis using alternate aldehydes (**7**). In this manner, 20 racemic angelmarin analogues (**8a–t**) were prepared as illustrated in Scheme 2. Columbianetin acetate (**9**) was obtained as a minor by-product (0–35 mol%) of this reaction.<sup>[38]</sup>


Two additional analogues, 2',3'-dihydroangelmarin **10** and 3,4,2',3'-tetrahydroangelmarin **11** were readily prepared via hydrogenation of ( $\pm$ )-angelmarin (**6**) over  $\text{Pt}(\text{OH})_2$  and Pd/C, respectively (Scheme 3).

To further examine the importance of the cinnamate subunit, carbamate **13** was prepared. Treatment of ( $\pm$ )-columbianetin **4** with triphosgene<sup>[39,40]</sup> in the presence of 4-dimethylami-

[a] Dr. J. Magolan, N. B. P. Adams, Dr. N. L. Hungerford, Dr. M. J. Coster  
Eskitis Institute for Cell and Molecular Therapies (N75)  
Griffith University, Nathan Campus  
Brisbane Innovation Park, Don Young Road, Nathan, QLD 4111 (Australia)  
Fax: (+61) 7 3735 6001  
E-mail: m.coster@griffith.edu.au

[b] H. Onozuka, Prof. H. Esumi  
Cancer Physiology Project, Research Center for Innovative Oncology  
National Cancer Center Hospital East  
6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 (Japan)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/cmdc.201100564>.




**Scheme 1.** Synthesis of (±)-angelmarin (6). *Reagents and conditions:* a) Allyl bromide,  $K_2CO_3$ , acetone, reflux, 6 h; b)  $PhNEt_2$ , reflux, 4 h; c) Grubbs II, 2-methyl-2-butene,  $CH_2Cl_2$ , reflux (slow addition of substrate); d) *m*-CPBA,  $K_2CO_3$ ,  $CH_2Cl_2$ , RT, 8 h; e) Meldrum's acid, toluene, reflux, 6 h; f) 4-hydroxybenzaldehyde, piperidine, pyridine, 70 °C, 12 h.

nopyridine (DMAP) gave reactive intermediate chloroformate **12**. It should be noted that safe handling procedures should be observed when using triphosgene.<sup>[41]</sup> Finally, addition of benzylamine to the chloroformate **12**, in situ, afforded carbamate **13** (Scheme 4).


In a preliminary effort to gauge the biological significance of the coumarin portion of the natural product, analogue **15** was prepared in two steps from dihydrobenzofuran tertiary alcohol **14**, as shown in Scheme 5.

In contrast to conventional anticancer activity, an inhibitor of the austerity pathway is cytotoxic to starvation-resistant cancer cells only under nutrient-deprived conditions. This anti-austerity activity can be quantified in terms of preferential cytotoxicity (PC). The evaluation is conducted using two assays in parallel, with PANC-1 cells in both nutrient-rich, such as Dulbecco's modified Eagle medium (DMEM), and NDM. The  $PC_{50}$  value is defined as the  $IC_{50}$  of a compound in NDM, where the compound is not cytotoxic in nutrient-rich medium. Synthetic angelmarin analogues were tested in vitro for preferential cytotoxicity against PANC-1 cells cultured in NDM.<sup>[20]</sup> These analogues exhibited a range of preferential cytotoxic potencies as shown in Table 1.

Racemic angelmarin (**6**) exhibits a  $PC_{50}$  value of 91 nM (c.f.,  $PC_{100}$  value of 26 nM obtained for the plant-derived (+)-enantiomer in the laboratories of Kadota et al.<sup>[25]</sup>). Our initial SAR investigations involved the replacement of the *para*-hydroxy substituent of (±)-angelmarin (**6**) with a variety of other groups (**8a–k**). Removal of the phenolic hydroxy group did not




**Scheme 2.** Synthesis of angelmarin analogues **8a–t**. *Reagents and conditions:* a) Meldrum's acid, toluene, reflux, 7 h; b) carboxylic acid **5**, RCHO **7**, piperidine, pyridine, 70 °C, 12 h.




**Scheme 3.** Hydrogenation of (±)-angelmarin (**6**) to yield compounds **10** and **11**. *Reagents and conditions:* a)  $H_2$  (1 atm),  $Pt(OH)_2$ , THF, RT, 4 h; b)  $H_2$  (1 atm), Pd/C, EtOAc, RT, 16 h.

entirely eliminate the cytotoxicity of the resultant compound (**8a**), but rather led to a threefold decrease in activity. In contrast, conversion of the phenol group in **6** to the corresponding acetate ester to give compound **8b**<sup>[42]</sup> resulted in a ninefold increase in preferential cytotoxicity ( $PC_{50}$  = 10 nM). Ester **8b**



**Scheme 4.** Synthesis of compound 13. *Reagents and conditions:* a) Triphosgene, DMAP,  $\text{CH}_2\text{Cl}_2$ , 1 h; b) benzylamine,  $\text{RT}$ , 16 h; then reflux, 16 h.



**Scheme 5.** Synthesis of compound 15. *Reagents and conditions:* a) Meldrum's acid, toluene, reflux, 7 h; b) 4-(trifluoromethyl)benzaldehyde, piperidine, pyridine,  $70^\circ\text{C}$ , 12 h.

**Table 1.** Structure–activity relationship data against PANC-1 cells under nutrient-deprived conditions.<sup>[B5]</sup>

Compound	$\text{PC}_{50}$ <sup>[a]</sup> [nM]	Compound	$\text{PC}_{50}$ <sup>[a]</sup> [nM]
(±)-angelmarin (6)	91 (8)	<b>8m</b>	730 (84)
(±)-columbianetin (4)	inactive <sup>[b,c]</sup>	<b>8n</b>	inactive <sup>[b]</sup>
<b>8a</b>	310 (72)	<b>8o</b>	7100 (720)
<b>8b</b>	10 (3)	<b>8p</b>	610 (97)
<b>8c</b>	5000 (560)	<b>8q</b>	140 (35)
<b>8d</b>	270 (15)	<b>8r</b>	79 (5)
<b>8e</b>	120 (34)	<b>8s</b>	310 (41)
<b>8f</b>	250 (22)	<b>8t</b>	320 (55)
<b>8g</b>	1000 (480)	<b>9</b>	inactive <sup>[b]</sup>
<b>8h</b>	2500 (740)	<b>10</b>	440 (76)
<b>8i</b>	23 (2)	<b>11</b>	inactive <sup>[b]</sup>
<b>8j</b>	inactive <sup>[b]</sup>	<b>13</b>	25 000 (5400)
<b>8k</b>	inactive <sup>[b]</sup>	<b>15</b>	3600 (780)
<b>8l</b>	700 (120)		

[a] Preferential cytotoxicity ( $\text{PC}_{50}$ ) corresponds to the  $\text{IC}_{50}$  value in nutrient-deprived medium for a compound that shows no cytotoxicity towards PANC-1 cells cultured in a nutrient-rich medium. Standard deviations are given in parentheses ( $n=4$ ). [b] No observed toxicity in nutrient-deprived medium at the highest test concentration of  $10\text{ mg mL}^{-1}$ . [c] Columbianetin was previously evaluated in this assay, see Ref. [25].

could potentially act as a prodrug with increased cell permeability, a hypothesis that is undergoing further investigation. Masking of the phenol moiety as the corresponding methyl ether, as in analogue **8c** resulted in a considerable loss of cytotoxicity ( $\text{PC}_{50}=5000\text{ nM}$ ), while replacing the phenolic hydroxy group with a methyl substituent (compounds **8d**) resulted in a threefold activity decrease (c.f., compound **6**). Two amine-containing analogues were examined; dimethylamino ana-


logue **8e** exhibits similar activity to the natural product ( $\text{PC}_{50}=120\text{ nM}$ ), whereas acetamide **8f** is inferior ( $\text{PC}_{50}=250\text{ nM}$ ) and 20-fold less potent than the analogous acetate ester (**8b**). 4-Fluoro- and 4-chloro-substituted analogues **8g** and **8h**, respectively, were active only at micromolar concentrations, with  $\text{PC}_{50}$  values of 1000 and 2500 nM, respectively. Interestingly, 2-fluoro derivative **8p** ( $\text{PC}_{50}=610\text{ nM}$ ) and 3,5-difluoro derivative **8q** ( $\text{PC}_{50}=140\text{ nM}$ ) were both more cytotoxic than 4-fluoro analogue **8g**, with **8q** exhibiting similar potency to (±)-angelmarin (**6**).  $\text{ok?}$  or should this be (+)-angelmarin?  $\text{ok?}$

We were gratified to discover that replacement of the phenol hydroxy moiety of angelmarin (**6**) with a trifluoromethyl substituent (analogue **8i**) resulted in a fourfold increase in potency ( $\text{PC}_{50}=23\text{ nM}$ ). Curiously, other electron-withdrawing substituents in place of the trifluoromethyl, such as nitrile (**8j**) and nitro (**8k**) groups, resulted in a complete loss of cytotoxicity. Notably, *meta*-trifluoromethyl-substituted analogue **8r** is also highly potent ( $\text{PC}_{50}=79\text{ nM}$ ). Detailed rationalisation of these results is limited by the whole-cell nature of the assay and the lack of information on the mechanism of action and biological target(s), and further studies are required to gain additional insight  $\text{ok?}$   $\text{ok?}$

Transposition of the phenolic hydroxy group of angelmarin to the *meta* position (**8l**) resulted in an approximately eightfold decrease in preferential cytotoxicity. 3,4-Dihydroxy analogue **8m** showed a similar decrease in activity. 2,3,4-Trimethoxyphenyl derivative **8n** was inactive, while 3-cyano derivative **8o** was weakly active, with a  $\text{PC}_{50}$  value of 7100 nM. Finally, replacing the phenyl ring with two heterocycles, furan **8s** and pyridine **8t**, resulted in decreased but still sub-micromolar cytotoxicity.

2',3'-Dihydroangelmarin analogue **10** displayed a fivefold decrease in preferential cytotoxicity ( $\text{PC}_{50}=440\text{ nM}$ ) in comparison with (±)-angelmarin (**6**), suggesting that either conformational rigidity associated with the *E* olefin or conjugation are important for highly potent antiausterity activity, but that this conjugated double bond is not absolutely essential. Further hydrogenation to the 3,4,2',3'-tetrahydro derivative (**11**) eliminated activity completely, highlighting the significance of the intact coumarin ring system. By comparison, truncated 2,3-dihydrobenzofuran **15**, which lacks the coumarin portion of angelmarin but includes the *para*-trifluoromethyl substituent (effectively incorporated into **8i**) showed only modest antiausterity activity ( $\text{PC}_{50}=3600\text{ nM}$ ). Interestingly, carbamate **13** displayed weak activity ( $\text{PC}_{50}=25000\text{ nM}$ ), suggesting that investigation of alternatives to the ester linkage could give interesting results.

Figure 1 depicts antiausterity activity dose–response curves for the most active analogues, compounds **8b** and **8i**, compared with (±)-angelmarin (**6**). Importantly, as illustrated for **8b** and **8i** in Figure 1, all of the active compounds tested (see Table 1) inhibit PANC-1 cells in NDM but not in normal growth medium (i.e., DMEM), thus displaying the necessary preferential cytotoxicity for the antiausterity strategy. Notably, all of the compounds were tested as the racemate, and so more potent activities might be expected for the corresponding pure enantiomers.  $\text{ok?}$   $\text{ok?}$



**Figure 1.** Cell viability versus concentration of a) (±)-angelmarin (**6**), b) acetate ester **8b** and c) trifluoromethyl analogue **8i** evaluated in PANC-1 cells grown in nutrient-deprived medium (NDM, ■) versus those cultured in normal growth medium (DMEM, ○ and ×). Cell viability was determined after incubation for 24 h. Measurements were performed in quadruplicate, and data shown are the mean ± standard error of the mean (SEM). ■■Caption ok?■■

In conclusion, a number of analogues of the potent antiausterity, anticancer natural product angelmarin have been synthesised and evaluated for their ability to inhibit the tolerance of PANC-1 cells to survive nutrient deprivation. We have elucidated preliminary structure–activity relationships, mainly focused on the *para*-hydroxycinnamate subunit of the natural product. Three analogues synthesised (**8b**, **8i** and **8r**) exhibit superior antiausterity activity compared with the racemic natural product **6**. The most potent of the novel compounds was acetate ester **8b**, which possibly acts as a prodrug with improved cell permeability. Compounds **8i** and **8r** feature trifluoromethyl substituents in the *para* and *meta* positions, with the *para*-substituted compound being the more potent. Preliminary results suggest the *E* cinnamate double bond is important for potent activity but not essential, whereas changes

to the coumarin moiety were not tolerated. The compounds described here provide a basis for the design of future analogues as molecular probes to undertake mechanism of action and target(s) identification studies. These efforts are underway and will be reported in due course.

## Experimental Section

**Antiausterity assay:** Human pancreatic carcinoma, epithelial-like cells (PANC-1) ■■ok?■■ were seeded in 96-well plates (1 × 10<sup>4</sup> per well) and incubated in fresh Dulbecco's modified Eagle's medium (DMEM) at 37 °C in an atmosphere of 5% CO<sub>2</sub>/95% air for 24 h. The cells were then washed with phosphate-buffered saline (PBS), and the medium was changed to either DMEM or nutrient-deprived medium (NDM; absence of glucose, amino acid, and serum), followed by immediate addition of serial dilutions of the test samples. After 24 h incubation, the cells were washed again with PBS, then DMEM (100 μL) with 10% WST-8 cell counting kit solution was added to the wells, and the plate was incubated for a further 2 h. Then, the absorbance of the wells at 450 nm was measured. The viable cell number was determined using a previously prepared calibration curve. None of the analogues evaluated were cytotoxic to PANC-1 cells cultured in DMEM medium up to 10 mg mL<sup>-1</sup>. PC<sub>50</sub> values correspond to the IC<sub>50</sub> values in nutrient-deprived medium; these were calculated based on nonlinear regression analysis of dose–response data (fitting data to four-parameter sigmoidal model) using GraphPad Prism version 5.0d for Mac OS X.

**General procedure for the preparation of **6** and **8a–t**:** A solution of (±)-columbianetin<sup>[34]</sup> (1.0 equiv) in toluene (10 mL mmol<sup>-1</sup> substrate) was treated with 2,2-dimethyl-1,3-dioxane-4,6-dione (1.0 equiv) and heated at reflux for 7 h, at which point TLC analysis indicated complete consumption of starting material. The reaction mixture was cooled to RT and concentrated in vacuo to yield crude carboxylic acid **5** as a yellow oil, which was immediately redissolved in pyridine (10 mL mmol<sup>-1</sup> substrate). Piperidine (1 drop mmol<sup>-1</sup> substrate) and appropriate benzaldehyde **7** (1.1 equiv) were added, and the reaction mixture was heated at 70 °C for 16 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with 5% aq HCl, water, brine. The organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography (gradient elution with EtOAc in petroleum spirits). Details of synthetic procedures and compound characterisation are provided in the Supporting Information.

## Acknowledgements

We thank the Australian Research Council (ARC) for funding (DP0986795) and a fellowship to M.J.C., and Griffith University (Queensland, Australia) for a postdoctoral fellowship to J.M. We gratefully acknowledge Dr. Hoan Vu (Griffith University) for assistance with mass spectrometry.

**Keywords:** antiausterity activity • antitumour agents • natural products • pancreatic cancer • structure–activity relationships

[1] R. M. Sutherland, *Science* **1988**, *240*, 177–184.

[2] P. Vaupel, F. Kallinowski, P. Okunieff, *Cancer Res.* **1989**, *49*, 6449–6465.

- [3] K. Koito, T. Namieno, T. Nagakawa, K. Morita, *AJR, Am. J. Roentgenol.* **1997**, *169*, 1263–1267.
- [4] K. Ranniger, R. M. Saldino, *Radiology* **1966**, *86*, 470–474.
- [5] N. A. Yassa, J. Yang, S. Stein, M. Johnson, P. Ralls, *J. Clin. Ultrasound* **1997**, *25*, 473–480.
- [6] T. Y. Reynolds, S. Rockwell, P. M. Glazer, *Cancer Res.* **1996**, *56*, 5754–5757.
- [7] J. Yuan, L. Narayanan, S. Rockwell, P. M. Glazer, *Cancer Res.* **2000**, *60*, 4372–4376.
- [8] J. Yun, A. Tomida, K. Nagata, T. Tsuruo, *Oncol. Res.* **1995**, *7*, 583–590.
- [9] A. Tomida, J. Yun, T. Tsuruo, *Int. J. Cancer* **1996**, *68*, 391–396.
- [10] J. Folkman, *N. Engl. J. Med.* **1971**, *285*, 1182–1186.
- [11] D. E. Richard, E. Berra, J. Pouyssegur, *Biochem. Biophys. Res. Commun.* **1999**, *266*, 718–722.
- [12] P. E. Thorpe, *Clin. Cancer Res.* **2004**, *10*, 415–427.
- [13] W. E. Fisher, D. H. Berger, *Int. J. Gastrointest. Cancer* **2003**, *33*, 79–88.
- [14] J. B. Fleming, R. A. Brekken, *J. Cell. Biochem.* **2003**, *90*, 492–501.
- [15] M. Korc, *Mol. Cancer* **2003**, *2*, 8.
- [16] D. Wei, X. Le, L. Zheng, L. Wang, J. A. Frey, A. C. Gao, Z. Peng, S. Huang, H. Q. Xiong, J. L. Abbruzzese, K. Xie, *Oncogene* **2003**, *22*, 319–329.
- [17] A. Masamune, K. Kikuta, T. Watanabe, K. Satoh, M. Hirota, T. Shimosegawa, *Am. J. Physiol. Gastrointest. Liver Physiol.* **2008**, *295*, G709–717.
- [18] K. Izuishi, K. Kato, T. Ogura, T. Kinoshita, H. Esumi, *Cancer Res.* **2000**, *60*, 6201–6207.
- [19] J. Magolan, M. J. Coster, *Curr. Drug Delivery* **2010**, *7*, 355–369.
- [20] H. Esumi, J. Lu, Y. Kurashima, T. Hanaoka, *Cancer Sci.* **2004**, *95*, 685–690.
- [21] J. Lu, S. Kunitomo, Y. Yamazaki, M. Kaminishi, H. Esumi, *Cancer Sci.* **2004**, *95*, 547–552.
- [22] S. Awale, J. Lu, S. K. Kalauni, Y. Kurashima, Y. Tezuka, S. Kadota, H. Esumi, *Cancer Res.* **2006**, *66*, 1751–1757.
- [23] P. Turner, E. Griffin, J. Whatmore, M. Shipman, *Org. Lett.* **2011**, *13*, 1056–1059.
- [24] T. Devji, C. Reddy, C. Woo, S. Awale, S. Kadota, D. Carrico-Moniz, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5770–5773.
- [25] S. Awale, E. M. Nakashima, S. K. Kalauni, Y. Tezuka, Y. Kurashima, J. Lu, H. Esumi, S. Kadota, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 581–583.
- [26] N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, *J. Nat. Prod.* **2007**, *70*, 1582–1587.
- [27] N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4688–4691.
- [28] N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, *Bioorg. Med. Chem.* **2008**, *16*, 8653–8660.
- [29] N. N. Win, S. Awale, H. Esumi, Y. Tezuka, S. Kadota, *Chem. Pharm. Bull.* **2008**, *56*, 491–496.
- [30] S. Awale, F. Li, H. Onozuka, H. Esumi, Y. Tezuka, S. Kadota, *Bioorg. Med. Chem.* **2008**, *16*, 181–189.
- [31] F. Li, S. Awale, Y. Tezuka, S. Kadota, *Bioorg. Med. Chem.* **2008**, *16*, 5434–5440.
- [32] S. Awale, T. Miyamoto, T. Z. Linn, F. Li, N. N. Win, Y. Tezuka, H. Esumi, S. Kadota, *J. Nat. Prod.* **2009**, *72*, 1631–1636.
- [33] F. Li, S. Awale, H. Zhang, Y. Tezuka, H. Esumi, S. Kadota, *J. Nat. Prod.* **2009**, *72*, 1283–1287.
- [34] J. Magolan, M. J. Coster, *J. Org. Chem.* **2009**, *74*, 5083–5086.
- [35] H. Jiang, Y. Hamada, *Org. Biomol. Chem.* **2009**, *7*, 4173–4176.
- [36] E. B. J. Harris, M. G. Banwell, A. C. Willis, *Tetrahedron Lett.* **2011**, *52*, 6887–6889.
- [37] D. J. Clarke, R. S. Robinson, *Tetrahedron* **2002**, *58*, 2831–2837.
- [38] Compound **9** was inactive in the antiausterity assay. Six analogues (**8a,g,h,k,p,s**) could not be separated from **9** via column chromatography (see supporting information). In these cases, a mixture of the analogue and **9** (minor component, composition determined by <sup>1</sup>H NMR) was evaluated in the assay and the results were corrected accordingly.
- [39] H. Zhao, C. Lee, P. Sai, Y. H. Choe, M. Boro, A. Pendri, S. Guan, R. B. Greenwald, *J. Org. Chem.* **2000**, *65*, 4601–4606.
- [40] W. A. Henne, D. D. Doorneweerd, A. R. Hilgenbrink, S. A. Kularatne, P. S. Low, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5350–5355.
- [41] S. B. Damle, *Chem. Eng. News* **1993**, *71*, 4–5.
- [42] Compound **8b** was prepared via acetylation of (±)-angelmarin (**6**), as detailed in the Supporting Information.

Received: November 29, 2011


Published online on ■■■■■, 0000




## COMMUNICATIONS

J. Magolan, N. B. P. Adams, H. Onozuka,  
N. L. Hungerford, H. Esumi, M. J. Coster\*

■ ■ - ■ ■

 **Synthesis and Evaluation of Anticancer Natural Product Analogues Based on Angelmarin: Targeting the Tolerance towards Nutrient Deprivation**



**Inspired by nature:** Angelmarin is an anticancer, natural product with potent antiausterity activity, that is, selective cytotoxic towards nutrient-deprived, resistant cancer cells. Through structure-activity relationship studies, three analogues were identified as lead compounds for the development of molecular probes for the investigation of the mode of action and biological targets of the antiausterity strategy. ■ ■ Text ok?

■ ■

## Genome-wide identification and annotation of HIF-1 $\alpha$ binding sites in two cell lines using massively parallel sequencing

Kousuke Tanimoto · Katsuya Tsuchihara ·  
Akinori Kanai · Takako Arauchi · Hiroyasu Esumi ·  
Yutaka Suzuki · Sumio Sugano

Received: 15 November 2010/Revised: 27 January 2011/Accepted: 1 February 2011/Published online: 19 February 2011  
© Springer Science+Business Media B.V. 2011

**Abstract** We identified 531 and 616 putative HIF-1 $\alpha$  target sites by ChIP-Seq in the cancerous cell line DLD-1 and the non-cancerous cell line TIG-3, respectively. We also examined the positions and expression levels of transcriptional start sites (TSSs) in these cell lines using our TSS-Seq method. We observed that 121 and 48 genes in DLD-1 and TIG-3 cells, respectively, had HIF-1 $\alpha$  binding sites in proximal regions of the previously reported TSSs that were up-regulated at the transcriptional level. In addition, 193 and 123 of the HIF-1 $\alpha$  target sites, respectively, were located in proximal regions of previously uncharacterized TSSs, namely, TSSs of putative alternative promoters of protein-coding genes or promoters of putative non-protein-coding transcripts. The hypoxic response of DLD-1 cells was more significant than that of TIG-3 cells with respect to both the number of target sites and the degree of induced changes in transcript expression. The Nucleosome-Seq and ChIP-Seq analyses of histone modifications revealed that the chromatin formed an open structure in regions surrounding the HIF-1 $\alpha$  binding sites, but this event occurred prior to the actual binding of HIF-1 $\alpha$ . Different cellular histories may be encoded by

chromatin structures and determine the activation of specific genes in response to hypoxic shock.

**Keywords** HIF-1 alpha · Hypoxia · ChIP-Seq · Transcriptome

### Introduction

Cancer cells in solid tumors are frequently exposed to limited oxygen environments because aberrantly growing cancer cells can cause a shortage of blood flow (Pouyssegur et al. 2006; Harris 2002; Keith and Simon 2007). Hypoxia is a term that is used to describe such cellular environments, which have an oxygen concentration between 0.02 and 3% (Thomas and Johannes 2007). It is important to understand the behavior of cancer cells under hypoxia because hypoxic conditions can be utilized to develop a therapeutic method to treat cancers (Fyles et al. 1998; Nordmark et al. 1996). If cancer cells were vulnerable to hypoxia, they would lose their ability to survive. In addition, controlling the hypoxic responses of cells may lead to new clinical therapeutics not only for solid tumors (Semenza 2003; Semenza 2010) but also for tissue ischemia and several inflammatory diseases (Fraisl et al. 2009; Semenza 2000).

Tumor cells adapt to hypoxic conditions through modifications of their gene expression patterns. For example, ATP metabolism changes from oxidative phosphorylation to anaerobic glycolysis. During this process, glucose uptake is enhanced, angiogenesis is induced to obtain a sufficient blood supply, and cell migration is promoted (Harris 2002; Pouyssegur et al. 2006; Gatenby and Gillies 2004; Hirota and Semenza 2006; Keith and Simon 2007). The central regulators of these changes in gene expression, which collectively lead to changes in cellular responses,

**Electronic supplementary material** The online version of this article (doi:10.1007/s11568-011-9150-9) contains supplementary material, which is available to authorized users.

K. Tanimoto · A. Kanai · T. Arauchi · Y. Suzuki (✉) ·  
S. Sugano

Graduate School of Frontier Sciences, The University of Tokyo,  
5-1-5 Kashiwanoha, Kashiwa, Chiba 277-8562, Japan  
e-mail: ysuzuki@k.u-tokyo.ac.jp

K. Tsuchihara · H. Esumi  
Cancer Physiology Project, Research Center for Innovative  
Oncology, National Cancer Center Hospital East, 6-5-1  
Kashiwanoha, Kashiwa, Chiba 277-8577, Japan



are the transcription factors hypoxia-inducible factors 1 and 2 (HIF-1/2) (Wang and Semenza 1995; Tian et al. 1997). Both HIF-1 and HIF-2 consist of two subunits, HIF- $\alpha$  and HIF- $\beta$  (or ARNT). The  $\alpha$ -subunit (HIF-1 $\alpha$ , HIF-2 $\alpha$ ) is the oxygen-sensitive subunit. Under hypoxic conditions, HIF-1 $\alpha$  (or HIF-2 $\alpha$ ) translocates from the cytoplasm to the nucleus and dimerizes with HIF- $\beta$ . The HIF heterodimer complex binds to a sequence motif called the hypoxia response element (HRE) and activates the expression of genes that are necessary for cellular survival under hypoxic conditions (Maxwell 2005; Poon et al. 2009). Although HIF-1 $\alpha$  demonstrates extensive sequence similarity to HIF-2 $\alpha$  and is regulated via the same mechanism, HIF-1 and HIF-2 are assumed to possess distinct biological roles. HIF-2 $\alpha$  expression is restricted to particular cell types, whereas HIF-1 $\alpha$  is expressed ubiquitously (Wiesener et al. 2003). Additionally, genes encoding glycolytic enzymes such as PGK1 and GLUT1 are unique targets of HIF-1 (Wenger et al. 2005; Raval et al. 2005).

Because of the inferred important roles of HIF-1 $\alpha$ , there have been several attempts to comprehensively identify HIF-1 $\alpha$  targets (Ortiz-Barahona et al. 2010). Although computational methods alone may still require further innovation due to the ambiguity of the HRE motif, the combination of computational methods and expression analyses using microarrays has proven to be a powerful approach (Benita et al. 2009). More recently, several papers have reported the identification of HIF-1 $\alpha$  binding sites based on chromatin immunoprecipitation and microarray (ChIP-chip) technology (Mole et al. 2009; Xia et al. 2009; Xia and Kung 2009). These studies have reported that about 400–500 of the HIF-1 $\alpha$  binding sites in the human genome and approximately 70% of the HIF-1 $\alpha$  binding sequences contain HREs.

Recent microarray-based approaches have produced far more information regarding HIF-1 targets than have conventional methods. However, these microarray methods have several limitations; namely, they cannot be used to analyze previously uncharacterized genes, for example, intergenic transcripts or transcripts of alternative promoters (Davuluri et al. 2008; Landry et al. 2003). In addition, the resolution of the data does not exceed the intervals of the DNA probes. The recently developed massively parallel sequencing technologies have provided a potential means to improve upon these methods. For example, the Illumina GA sequencer can sequence 200–250 million sequences per run. By utilizing Illumina GA and ChIP technologies (ChIP-Seq), the binding sites of several transcription factors have been reported (Valouev et al. 2008; Robertson et al. 2007; Kwon et al. 2009; Welboren et al. 2009; Park 2009). On the other hand, we also developed a method for sequencing the 5'-ends of mRNAs by combining our oligo-capping technique with the Illumina GA sequencer

(Tsuchihara et al. 2009). This method, which we named TSS-Seq, enables us to obtain precise information regarding the positions of the transcriptional start sites (TSSs) together with their expression levels in a high-throughput manner. In our previous report, we applied TSS-seq to observe gene expression changes in response to hypoxia in several cell lines (Tsuchihara et al. 2009).

To identify TSSs with hypoxic responses elicited directly by HIF-1 $\alpha$  binding, we performed HIF-1 $\alpha$  ChIP analysis and combined the resultant data with the TSS-Seq data. Furthermore, we carried out Illumina GA sequencing analysis using micrococcal nuclease-digested genomic DNA (Nucleosome-Seq) (Albert et al. 2007; Jiang and Pugh 2009; Schones et al. 2008). We examined the changes in nucleosome structure caused by HIF-1 $\alpha$  binding and the subsequent transcriptional activation. We also examined the chromatin statuses surrounding the HIF-1 $\alpha$  binding sites by ChIP-Seq analysis of RNA polymerase II (pol II) and a series of histone modifications, namely, H3K4 trimethylation (H3K4me3), H3 acetylation (H3Ac) and H3K27 trimethylation (H3K27me3) (Barski et al. 2007). H3K4me3 and H3Ac are known to be characteristic of an open chromatin structure, and H3K27me3 is characteristic of a closed chromatin structure. A colorectal cancer epithelial cell line (DLD-1) and a normal embryonic lung fibroblast cell line (TIG-3) were used for these analyses. Here, we report the genome-wide identification and characterization of HIF-1 targets using several types of massively parallel sequencing analyses. We further compared the observed targets between DLD-1 cells and TIG-3 cells to examine the cellular responses characteristic of these cells.

## Materials and methods

### Accession numbers

The short-read tag sequences used in the present work have been deposited in DDBJ under the following accession numbers: SRA003625 (TSS-Seq data), DRA000007-000008 and DRA000190-000191 (pol II ChIP-Seq data), DRA000073-000075 and DRA000003 (Nucleosome-Seq data), DRA000178-000185 (HIF-1 $\alpha$  ChIP-Seq data), DRA000277-000284 (H3K4me3 ChIP-Seq data), DRA000285-000288 and DRA000293-000296 (H3Ac ChIP-Seq data) and DRA000289-000292 and DRA000297-000300 (H3K27me3 ChIP-Seq data).

The data generated in this study are accessible via following URL in BED file format: <http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/chip.tar.gz> (ChIP-Seq data), [http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/nucleosome\\_bed.tar.gz](http://www.dbtss.hgc.jp/cgi-bin/downloader2.cgi/nucleosome_bed.tar.gz) (Nucleosome-Seq data), <http://www.dbtss.hgc.jp/>



[cgi-bin/downloader2.cgi/rnaseq.tar.gz](http://cgi-bin/downloader2.cgi/rnaseq.tar.gz) (RNA-Seq data) and [ftp://ftp.hgc.jp/pub/hgc/db/dbtss/dbtss\\_ver7/bed\\_files/](http://ftp.hgc.jp/pub/hgc/db/dbtss/dbtss_ver7/bed_files/) (TSS-Seq data).

### Cell culture

The human colorectal cancer cell line DLD-1 (Japan Health Science Research Resources Bank cell number JCRB9094) was maintained in Dulbecco's Modified Eagle's Medium (DMEM, Nissui) Supplemented with 10% fetal calf serum, 4.5 g/l glucose, and antibiotics. The human normal embryonic lung fibroblast cell line TIG-3 (Japan Health Science Research Resources Bank cell number JCRB0506) was maintained in MEM (GIBCO) Supplemented with 10% fetal calf serum and antibiotics. The cells were cultured under standard conditions and subjected to hypoxic shock (1% O<sub>2</sub>) in a similar manner.

### Construction of the ChIP-seq library and analysis of ChIP-seq tags

DLD-1 and TIG-3 cells ( $1 \times 10^8$ ) were fixed using a final concentration of 1% formaldehyde at room temperature for 10 min. To quench the reaction, 150 mM (final concentration) glycine was added to the samples followed by a 5-min incubation. The cells were washed twice with PBS, harvested and then lysed in 5 ml of Lysis Buffer 1 (50 mM HEPES–KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100). The lysates were incubated at 4°C for 10 min and centrifuged at 1,500 rpm for 5 min at 4°C. The pellets were then resuspended in 5 ml of Lysis Buffer 2 (10 mM Tris–HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), incubated at room temperature for 10 min, and centrifuged at 1,500 rpm for 5 min at 4°C. The pellets were resuspended in 1 ml of Lysis Buffer 3 (10 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% *N*-lauroylsarcosine) and sonicated with 18 cycles of 30 s each on ice using a sonicator (TOMY SEIKO). One hundred microliters of 10% Triton-X 100 was added to the samples, and the cell lysates were centrifuged for 10 min. Fifty microliters of the supernatant was saved for the controls (named whole cell extract (WCE) DNA). Washed magnetic beads bound to 10 µg of rabbit polyclonal anti-HIF-1α antibody (Novus Biologicals, Inc., NB100-134), monoclonal anti-RNA polymerase II antibody (Abcam, ab817), monoclonal anti-H3K4me3 antibody (ab1012), polyclonal anti-H3Ac antibody (Millipore, 06-599) or monoclonal anti-H3K27me3 antibody (ab6002) was added to the supernatant. The samples were rotated at 4°C overnight and washed 8 times with 1 ml of wash buffer (50 mM HEPES–KOH, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate) and once

with TE buffer containing 50 mM NaCl. The sample was then eluted with 200 µl of elution buffer (1 M Tris–HCl, pH 8.0, 0.5 M EDTA, pH 8.0, 1% SDS) at 65°C for 15 min. The supernatant was transferred to a new tube and incubated at 65°C overnight. Concurrently, 150 µl of elution buffer was added to the saved WCE-DNA, and the samples were incubated at 65°C overnight. Next, 200 µl of TE and 8 µl of 10 mg/ml RNase A (Funakosi) were added to the IP and WCE DNA samples. The samples were then incubated at 37°C for 2 h. Subsequently, 4 µl of 20 mg/ml proteinase K (Takara) was added to the samples, which were then incubated at 55°C for 2 h. The DNA samples were purified using TRIzol LS (Invitrogen) and ethanol precipitation. Samples destined for ChIP-seq by Illumina GA were prepared according to the manufacturer's instructions.

### Computational procedures

The generated ChIP-Seq tags were mapped to the reference human genome sequences (hg18), and the tags that were uniquely mapped allowing two-base mismatches were used. The binding sites of HIF-1α, RNA polymerase II and histone modifications, based on the short-read tag information, were identified as follows: the regions encompassed by the mapped tag sequences were extended to 120 bp, which reflected the insertion sites of the sample DNA fragments. For each genomic position, the number of overlapping extended tags was counted. Based on the calculated tag information, the sum of the included tags was evaluated to determine whether more than a tenfold difference between the immunoprecipitation (IP) and the whole cell extract (WCE) was present. Genomic regions in which positive enrichment of the tags continued for more than 121 bp were then selected. Among these regions, those containing more than 5 different sequence tags were identified as potential HIF-1α and RNA polymerase II binding sites. We normalized the tag counts for each region to tags per million (ppm) and divided the results by the length of the region (ppm/bp). These values were determined as the peak strength in this study. In the HIF-1α ChIP-Seq analysis, if the identified regions demonstrated an overlap between 1% O<sub>2</sub> (hypoxia) and 21% O<sub>2</sub> (normoxia), regions with more than a twofold (hypoxia/normoxia) change in peak strength were identified as “bindings enriched in hypoxia.” The statistical significance determined for this selection procedure compared to the background rate was evaluated using Poisson probabilities as previously described (Robertson et al. 2007):  $P(x, \lambda) = 1 - \sum_{t=0}^{x-1} \frac{e^{-\lambda} \lambda^t}{t!}$ , where  $P(x, \lambda)$  is the probability of enrichment,  $\lambda$  is the expected tag number in the 121-bp



window calculated for the WCE sample, and  $x$  is the observed tag number in the 121-bp window.

To analyze the gene expression changes in the transcription factors in DLD-1 and TIG-3 cells, 140 transcription factors were selected in TRANSFAC (Rel. 2010.1). The consensus sequences of the transcription factors were also evaluated using MATCH with cutoff values determined using minFP, which minimizes false-positive results. The enrichment of the detected putative binding sites in the HIF-1 $\alpha$  target genes in DLD-1 cells, TIG-3 cells and both cell lines were evaluated by calculating the hypergeometric distributions. Putative transcription factor binding sites that were statistically significantly enriched ( $P < 0.05$ ) in the respective groups were selected. For details, see Supplementary Table 3.

#### TSS-Seq analysis and RNA-Seq analysis of polysome fractions

TSS-Seq tags were prepared and analyzed as described in the reference (Tsuchihara et al. 2009). After clustering the TSS-tags using 500-bp bins, representative TSSs were selected as the position from which the largest number of TSS tags was mapped. The selected representative TSSs were used for further analyses.

For the RNA-Seq analysis of polysome-incorporated RNA, the cytoplasmic fraction was isolated from DLD-1 cells using the PARIS Kit (Ambion, AM1921). Polysome-incorporated fractions were further fractionated from cytoplasmic fraction using the sucrose-density-gradient method described in the reference (Koritzinsky and Wouters 2007). Thirty-six-base-pair single-end-read RNA-Seq tags were generated using an Illumina GA sequencer according to the standard protocol. RNA-Seq tags that were mapped to the human reference genome sequences without any mismatches were used. RNA-Seq tags corresponded to RefSeq transcripts when their genomic coordinates overlapped. Details of the characterization and the RNA-Seq libraries are presented in Supplementary Fig. 6.

#### Construction of the nucleosome-Seq library and analysis of nucleosome tags

Cells were cultured to 80% confluence and treated with micrococcal nuclease to generate mononucleosomes using the ChIP-IT Express Enzymatic Kit (active motif). The cells were formaldehyde-cross-linked prior to the nucleosome isolation. Cross-linking was performed with fixation solution (DMEM, 1% formaldehyde) for 10 min at room temperature. The cells were then washed with PBS, and the cross-linking reaction was stopped by incubating the cells with a glycine quenching solution (PBS glycine buffer) for 5 min at room temperature. After the dishes were washed

with PBS, an ice-cold cell scraping solution was added. The cells were then harvested and resuspended in ice-cold lysis buffer, incubated on ice for 30 min, and homogenized by 15–20 strokes with a Dounce homogenizer. The nuclei were suspended in digestion buffer and pre-warmed in this solution for 5 min at 37°C. An enzymatic cocktail (200 U/ml) was added to the sample, and the digestion reaction was incubated at 37°C for 15 min. After the reaction was stopped with EDTA, the nuclei were pelleted by centrifugation, and the supernatants were collected. Formaldehyde cross-linking was reversed by the addition of 5 M NaCl and RNase followed by an incubation at 65°C for more than 4 h. Proteinase K was added to the samples, and the mixtures were incubated at 42°C for 1.5 h. DNA was purified by phenol/chloroform extraction and ethanol precipitation. The extracted DNA was used for the sample preparation for Illumina GA according to the manufacturer's instructions.

#### Real-time PCR analysis


Real-time PCR primers were designed within the identified HIF-1 $\alpha$  binding sites. Primer3 (<http://www.frodo.wi.mit.edu/primer3/>) was used to design the primers. The fold enrichment at each locus was calculated according to the  $\Delta\Delta C_t$  method. The primer sequences are presented in Supplementary Table 1.

## Results and discussion

### Identification of HIF-1 $\alpha$ binding sites

Using 22,315,752 and 15,389,864 36-bp single-end-read sequence tags generated for the ChIP-Seq analysis of DLD-1 and TIG-3 cells (Supplementary Fig. 1), we searched for HIF-1 $\alpha$  binding sites by quantifying the local enrichment of tags (Robertson et al. 2007) (see “Materials and methods”). Next, we classified the putatively identified binding sites as “hypoxia-responsive” or “non-hypoxia-responsive.” “Hypoxia-responsive” binding sites were the regions identified only under hypoxia or the regions in which the associated ChIP-Seq tags were enriched more than twofold under hypoxia. “Non-hypoxia-responsive” binding sites were those that did not show more than a twofold change in tag concentrations between normoxia and hypoxia. A typical example for each category is shown in Fig. 1a. As summarized in Table 1, there were 531 and 616 “hypoxia-responsive” HIF-1 $\alpha$  binding sites in DLD-1 and in TIG-3 cells, respectively. As shown in Fig. 1b, we selected and validated 29 of the identified HIF-1 $\alpha$  binding sites by real-time PCR. We confirmed that 28 cases (97%) showed at least a fourfold signal enrichment in the immunoprecipitated

**Fig. 1** Identification of HIF-1 $\alpha$  binding sites. **a** Representative sites identified as “hypoxia-responsive”, “hypoxia-enriched” and “non-hypoxia-responsive” HIF-1 $\alpha$  binding sites. The definitions for each group are described in the text. The former two categories were considered for identifying HIF-1 $\alpha$  target genes. *Blue* and *red* horizontal bars indicate 36-bp sequence tags that were mapped to the forward and reverse strands, respectively. The genomic coordinates and RefSeq IDs of the indicated transcript models are shown in the margin. **b** Validation of the identified binding sites by ChIP-Seq analysis using real-time PCR. The fold enrichment of the signals determined for immunoprecipitated samples compared with the background noise is shown on a log scale for 29 selected cases. Genomic regions as specified in Supplementary Table 1 were used for the validation analysis. For details, see “Materials and methods” and Supplementary Fig. 2. Error bars represent the standard deviations of triplicate experiments. (Color figure online)



samples compared with the background noise (see also Supplementary Fig. 2 for agarose gel images of the PCR bands).

Using the identified “hypoxia-responsive” HIF-1 $\alpha$  binding sites, we searched for the HRE motif. We found that 441 (83%) and 413 (67%) regions contained the HRE motif in DLD-1 and in TIG-3 cells, respectively (fourth column, Table 1). These frequencies were similar to those reported in previous HIF-1 $\alpha$  ChIP-chip studies (Mole et al. 2009; Xia et al. 2009), although the detected genomic regions containing the HIF-1 $\alpha$  binding sites were shorter in length due to the improved resolution of the analysis (the lengths of the detected binding sites were more than threefold shorter than those detected in previous studies using ChIP-chip, which reflected the intervals of the designed DNA probes (Mole et al. 2009); see also Supplementary Fig. 3a). Occasionally, two or three adjacent core HRE motifs were detected in a single gene, such as the

genes encoding transferrin and the glucose transporter (Wenger et al. 2005). We examined the number of HRE motifs and the ChIP-Seq tag concentrations and found no correlation between them (Supplementary Fig. 3b). The HRE motif plays a role in defining the binding positions but may not contribute directly to the binding strength.

Transcripts in the proximal regions of the identified HIF-1 $\alpha$  binding sites


In DLD-1 and TIG-3 cells, 193 (37%) and 161 (26%) of the “hypoxia-responsive” HIF-1 $\alpha$  binding sites, respectively, were located from 10 kb upstream to 1 kb downstream of the 5'-ends of the RefSeq transcript models (23771 transcript models in 18,001 genes in total). The locations of the binding sites relative to the RefSeq genes are summarized in Venn diagrams in Fig. 2a. For these binding sites, we analyzed the distributions of the relative distances from the



**Table 1** Number of HIF-1 $\alpha$  binding sites

	Hypoxia-responsive binding sites			Non-hypoxia-responsive binding sites
	Hypoxia-specific	Hypoxia-enriched	Total binding sites	
DLD-1	499	32	531	441 (83%)
TIG-3	599	17	616	413 (67%)

The number of identified HIF-1 $\alpha$  binding sites in DLD-1 and TIG-3 cells. “Hypoxic-responsive” HIF-1 $\alpha$  binding sites are the sum of the “hypoxia-specific” binding sites, which were detected only under hypoxia, and the “hypoxia-induced” binding sites, which were detected under normoxia, but the ChIP-Seq tag concentration was induced more than twofold under hypoxia. Note that most of the identified “hypoxia-responsive” HIF-1 $\alpha$  binding sites are “hypoxia-specific.” *HRE* hypoxia response element, 5'-RCGTG-3'




**Fig. 2** Characterization of RefSeq transcripts. **a** Genomic locations of the identified HIF-1 $\alpha$  binding sites in DLD-1 and TIG-3 cells compared to the RefSeq transcript models. Positions relative to the RefSeq genes are shown. When a RefSeq gene contained multiple transcript models, all of the transcript models were considered.

**b** Distributions of the distances from the identified binding sites to the 5'-ends of the RefSeq transcript models. Blue and red bars represent DLD-1 and TIG-3 cells, respectively. When a RefSeq gene contained multiple transcript models, all of the transcript models were considered and counted redundantly. (Color figure online)

5'-ends of each RefSeq transcript model (Fig. 2b). When a RefSeq gene contained multiple transcript variant models, all of the variants were considered and counted redundantly. We found that approximately 70% of the binding sites were located within 1 kb of the 5'-ends of the RefSeq transcript models, which is consistent with previous estimations (Lin et al. 2009; Mole et al. 2009).

To directly examine the positions of the TSSs and their expression changes in response to HIF-1 $\alpha$  binding in DLD-1 and TIG-3 cells, we used TSS-Seq data. This dataset

contains a total of 141,590,200 TSS tags, each of which corresponds to the cap site of a single mRNA (Tsuchihara et al. 2009). We clustered the TSS tags into TSS clusters (TSCs) to separate individual putative promoter units (see the reference (Tsuchihara et al. 2009) for details). The numbers of TSS tags were normalized to parts per million mapped TSS tags, and the sum of the TSS tag concentrations associated with the same TSC was defined as the expression level of the TSC. The fold changes of each TSC in response to hypoxia were evaluated as the changes in



**Fig. 3** Correlations of HIF-1 $\alpha$  target genes and their expression levels. **a** Venn diagram of the number of identified HIF-1 $\alpha$  target genes in DLD-1 and TIG-3 cells. The *upper panel* shows the total number of genes for which HIF-1 $\alpha$  binding sites were identified in the flanking regions. The *lower panel* shows the identified target genes with expression levels that were induced more than twofold under hypoxia, as determined on the basis of digital TSS tag counts. **b** Fold changes in the expression levels of the identified target genes in HIF-1 $\alpha$  knock-down cells. The fold changes were calculated as the TSS tag

concentration in knock-down cells/TSS tag concentration in normal cells. The *bars* below the axis represent cases in which gene expression was repressed in HIF-1 $\alpha$  knockdown cells in comparison to normal cells (83% of all cases). See Supplementary Fig. 4 for details of the validation analysis. **c** Distributions of the fold changes in expression levels of the genes bound by HIF-1 $\alpha$  in DLD-1 and TIG-3 cells, as determined by the digital TSS tag counts. The statistical significance of the difference in distributions was evaluated using the Wilcoxon rank sum test ( $P = 1e-13$ )


TSS tag concentrations under hypoxia versus normoxia. [The statistics obtained for the TSS tags are shown in Supplementary Fig. 4. Additional details can be also found in the reference (Tsuchihara et al. 2009).]

We combined the ChIP-Seq and TSS-Seq data to examine the transcriptional consequences of HIF-1 $\alpha$  binding. Among the above-mentioned binding sites, which were associated with the RefSeq genes, the TSS-Seq data revealed the presence of TSCs that overlapped the 5'-ends of the RefSeq transcript models in 220 and 185 genes in DLD-1 and TIG-3 cells, respectively (note that a particular binding site sometimes corresponds to multiple TSCs). Particularly, in 121 and 48 genes, the expression levels of the TSCs were induced more than twofold under hypoxia, respectively, (Fig. 3a; referred to as “HIF-1 $\alpha$  target genes/TSCs” hereafter). As shown in Supplementary Fig. 4c, the expression levels of representative target genes were validated by real-time PCR. We also performed similar TSS-Seq analyses in HIF-1 $\alpha$  knock-down cells. Of the 121 putative HIF-1 $\alpha$  target genes in DLD-1 cells, the hypoxia-responsive induction of gene expression was repressed in 100 cases in the TSS-Seq analysis in which HIF-1 $\alpha$  was

knocked down (83%; Fig. 3b). Supplementary File contains the top 25 HIF-1 $\alpha$  target genes, which are ranked according to their fold change at the transcription level in DLD-1 and TIG-3 cells (see also Supplementary Fig. 5 for an example of HIF-1 $\alpha$  target genes identified by ChIP-Seq and TSS-Seq analyses).

We further analyzed whether the identified HIF-1 $\alpha$  targets were translated into proteins. To achieve this goal, we analyzed the RNAs that were incorporated into the translating ribosome (polysome) fractions. RNA was isolated from DLD-1 cells that were cultured under normal and hypoxic conditions. Polysome-incorporated RNA was isolated from each cell culture by sucrose density gradient purification of the cytoplasmic RNA (see “Materials and methods”). A total of 46,170,807 36-bp single-end-read RNA-Seq tags were generated, and the abundance of the transcripts was evaluated by digital counts of the RNA-Seq tags (Supplementary Fig. 6). We expected that the changes in the RNA-Seq tags could be used as an indicator to measure gene expression changes at the translational level. As shown in Fig. 4, the levels of RNA-Seq tags for the putative HIF-1 $\alpha$  target genes were significantly induced in





**Fig. 4** Fold change in the amount of RNA present in polysome fractions in response to hypoxic stimuli. Distributions of the fold changes of transcripts in the polysome fractions in response to hypoxia, as determined by digital RNA-Seq tag counts. Fold changes in HIF-1 $\alpha$ -bound target genes for which transcriptional induction was observed (*left*), HIF-1 $\alpha$ -bound genes for which no transcriptional induction was observed (*middle*) and all RefSeq genes (*right*) are shown. Statistical significance in the differences in the distributions were evaluated using the Wilcoxon rank sum test and are shown in the margin

the polysome fractions in response to hypoxia, which suggested that a majority of the gene expression was induced at the protein level, too. Taking these results together, we concluded that we had identified direct targets of HIF-1 $\alpha$  that were bound by HIF-1 $\alpha$  and that the expression of these targets was induced at transcriptional and translational levels.

#### Target genes of HIF-1 $\alpha$ in DLD-1 and TIG-3 cells

We compared the HIF-1 $\alpha$  target genes in DLD-1 cells and TIG-3 cells. We found that 18 genes overlapped, and the remaining genes were unique to each cell type. We performed Gene Ontology (GO) term (Ashburner et al. 2000) analysis to examine whether the gene groups of particular functional categories were enriched in the respective cell types. Seven and four GO terms were enriched (hypergeometric distribution;  $P < 0.01$ ) in DLD-1 and TIG-3 cells, respectively (see also Supplementary Tables 2a and 2b for the full list). Of these, GO term “glycolysis” (GO: 0006096) was commonly enriched. “Response to hypoxia” (GO: 0001666) was enriched only in DLD-1 cells. It was intriguing that the genes belonging to this GO term, which

are considered to have indispensable roles in the maintenance of homeostasis under hypoxic conditions, were selectively enriched in DLD-1 cells (proportion test;  $P = 0.0001$ ). TIG-3 cells, which represent a normal cell type and thus have never been exposed to hypoxia, may not be robust in hypoxia because several essential genes are not induced.


We also found that the hypoxic response of DLD-1 cells was more significant than that of TIG-3 cells, both in the number of target genes and in the degree of expression induced (Wilcoxon rank sum test;  $P = 3e-13$ ). Figure 3c illustrates the fold expression changes in DLD-1 and TIG-3 cells.

To further characterize the molecular mechanisms underlying the differential gene expression observed between the cell types, we assessed the global expression patterns of transcription factors in DLD-1 cells and TIG-3 cells on the basis of digital TSS tag counts for the genes encoding transcription factors. We used a total of 140 well-characterized transcription factors that were registered in the representative database TRANSFAC. As shown in Supplementary Fig. 7, transcriptional induction of the transcription factor genes was more significant in DLD-1 cells than in TIG-3 cells ( $P = 0.02$ ) (see also Supplementary Fig. 8 for an example). To specify the transcription factors that might be responsible for the activation of particular genes, we examined the enrichment of consensus binding sites for specific transcription factors in the surrounding regions of HIF-1 $\alpha$  binding sites. We examined the genes which were identified as HIF-1 $\alpha$  target genes in DLD-1 cells, TIG-3 cells or in both cell types. We found that fourteen consensus binding sequences were enriched around the HIF-1 $\alpha$  binding sites in total. Of these sequences, four transcription factors were transcriptionally induced more than twofold in the TSS-Seq analysis in the corresponding cell types (see Supplementary Table 3 for the full list). These transcription factors may regulate the transcription of HIF-1 $\alpha$  target genes in cooperation with HIF-1 $\alpha$  in DLD-1 cells or TIG-3 cells. It is also interesting to speculate that the coordinated expression of the transcription factors might have been acquired throughout cellular history. DLD-1 cells originated from a solid tumor that experienced severe hypoxic conditions (Rajaganeshan et al. 2009; Schmitz et al. 2009). Similar analyses will be necessary in the future to assess a greater variety of cell types in order to validate this hypothesis.

#### Epigenetic regulation in regions surrounding HIF-1 $\alpha$ binding sites

We also analyzed the nucleosome structure in the surrounding regions of the HIF-1 $\alpha$  binding sites in DLD-1 and TIG-3 cells. It has been reported that nucleosomes acquire





**Fig. 5** Nucleosome structures in regions surrounding HIF-1 $\alpha$  binding sites. Nucleosome occupancy in regions surrounding the identified HIF-1 $\alpha$  binding sites. The calculated nucleosome occupancy scores (y-axis) are plotted against every genomic coordinate (x-axis). The computational procedure used to calculate the nucleosome occupancy score is described in “Materials and methods”. The putative binding site of

HIF-1 $\alpha$ , represented by HRE, was defined as position 0 (x-axis). *Blue* and *red* lines indicate the nucleosome occupancy scores under hypoxia and normoxia, respectively. Only the HIF-1 $\alpha$  binding sites for which the associated TSCs were induced by more than twofold were used in the plot for each cell type. For details regarding the Nucleosome-Seq datasets, see Supplementary Fig. 9. (Color figure online)


an open chromatin structure following the binding of transcription factors (Zhang et al. 2009). To analyze the nucleosome structure, Nucleosome-Seq (Albert et al. 2007; Jiang and Pugh 2009; Schones et al. 2008) was used in DLD-1 and TIG-3 cells. We generated a total of 130,088,634 36-bp sequence tags from micrococcal nuclease-digested genomic DNA and calculated the occupancy of the nucleosome according to a previously reported procedure (Albert et al. 2007) (Supplementary Fig. 9; see “Materials and methods”). As shown in Fig. 5, the occupancy score for DLD-1 cells dropped sharply in the regions surrounding hypoxia-responsive HIF-1 $\alpha$  binding sites under hypoxia (Fig. 5, blue line in the left panel), which suggested that the nucleosome structures formed an open structure. On the other hand, the occupancy scores for HRE motifs that were not bound by HIF-1 $\alpha$  did not indicate such an open structure (Supplementary Fig. 10). The same results were obtained for TIG-3 cells (Fig. 5, blue line in the right panel). These results indicated that only a part of HRE motifs had an open nucleosome structure suitable for subsequent transcriptional activation, although HRE motifs were present throughout the human genomic sequences. Previous HIF-1 $\alpha$  ChIP-chip studies have reported that less than 1% of the HRE motifs within the genomic sequences that are located in regions used for the microarrays are bound by HIF-1 $\alpha$  (Mole et al. 2009; Wenger et al. 1998, 2005). Epigenetic regulation of the human genome plays an essential role in specifying the binding sites of HIF-1 $\alpha$  in addition to the consensus binding sequences.

Interestingly, for the HIF-1 $\alpha$  target HRE, we observed that the open chromatin structure was already formed under normoxia (Fig. 5, red line in the left panel for DLD-1 cells and in the right panel for TIG-3 cells). On the other hand,

the TSS tags induced by hypoxia for the approximately 1-kb downstream regions were first detected after the binding of HIF-1 $\alpha$  under hypoxia. To further examine the chromatin status surrounding HIF-1 $\alpha$  binding regions, we analyzed the histone modification patterns (H3K4me3, H3Ac and H3K27me3) and binding status of pol II by ChIP-Seq analyses. The numbers of sequence tags generated for each analysis are shown in Supplementary Fig. 11 and 12. Figure 6 shows the observed histone modification and pol II binding profiles in the regions surrounding the HIF-1 $\alpha$  binding sites. Consistent with the TSS-Seq profiles, pol II binding first increased under hypoxia. On the other hand, the histone markers for active chromatin, H3K4me3 and H3Ac, were already observed under normoxia, whereas the marker for silent chromatin, H3K27me3, was absent throughout the hypoxic shock period (Fig. 6b–d, f–h). These results suggested that open and active chromatin structures originally formed under normoxia, irrespective of the pol II binding status and downstream transcriptional induction. The cells seemed to stay in a somewhat prepared status for a hypoxic response. The cells might memorize their histories with respect to the chromatin status. Such a prepared status of the cells via epigenetic regulation has been discussed in previous reports (Heintzman et al. 2007; Kim et al. 2008; Mole et al. 2009); however, this is the first study to provide direct evidence supporting this possibility.

#### HIF-1 $\alpha$ regulation of alternative promoter variants

One of the greatest advantages of using ChIP-Seq and TSS-Seq is that the HIF-1 $\alpha$  binding sites and subsequent transcriptional induction can be detected separately for alternative promoters. Of the identified 121 and 48 HIF-1 $\alpha$



**Fig. 6** Profiles of RNA polymerase II binding and histone modification in the regions surrounding HIF-1 $\alpha$  binding sites. Average tag concentrations (y-axis) obtained in the ChIP-Seq analyses of pol II (a, e), H3K4me3 (b, f), H3Ac (c, g) and H3K27me3 (d, h) are plotted for each genomic coordinate (x-axis). The observed profiles are shown for DLD-1 (a–d) and TIG-3 cells (e–h). In each panel, red and blue lines represent the tag counts under hypoxia and normoxia for

the IP samples, respectively. Green and sky blue lines represent the results obtained for the background control (whole cell extract samples). The putative binding site of HIF-1 $\alpha$ , represented by HRE, was defined as position 0 (x-axis). For each panel, the tag counts for 290 and 221 binding sites, which have HRE among the HIF-1 $\alpha$  target TSCs (either genic or intergenic TSCs), were averaged in DLD-1 and TIG-3 cells, respectively. (Color figure online)

target genes, 15 and 5 target genes had more than one alternative promoter variant in the RefSeq transcript models in DLD-1 and TIG-3 cells, respectively (see Supplementary Fig. 13 for one of these examples). It should

also be noted that the majority of HIF-1 $\alpha$  target alternative promoters are novel promoters. One hundred and ninety-three and 123 TSCs were identified as previously uncharacterized putative alternative promoters in DLD-1 and



**Table 2** Number of TSCs associated with binding sites located in genic and intergenic regions

	#Binding sites	#HIF-1 $\alpha$ bound genes in which TSCs overlapped the 5'-end of RefSeq transcript models	#HIF-1 $\alpha$ target genes
<b>a</b>			
DLD-1	193	220	121
TIG-3	161	185	48
	#Previously characterized AP TSCs (#genes)		#Newly identified AP TSCs (#genes)
<b>b</b>			
DLD-1	15 (15)		193 (89)
TIG-3	5 (4)		123 (80)
	#Binding sites	#Intergenic TSCs	#Intergenic TSCs located in repetitive regions
<b>c</b>			
DLD-1	207	262	21
TIG-3	289	105	21

**a** The number of genes that were bound to HIF-1 $\alpha$  in the flanking regions (from 10 kb upstream to 1 kb downstream of the binding sites) of the 5'-ends in the RefSeq transcript models. "HIF-1 $\alpha$  target genes" indicate genes with expression levels that were induced more than twofold by hypoxia

**b** The number of HIF-1 $\alpha$  target TSCs corresponding to alternative promoters (APs) which had been characterized as RefSeq transcript variants (first column) and those which were newly identified in this study (second column). The numbers of corresponding genes are shown in parentheses

**c** The number of HIF-1 $\alpha$  target TSCs located in intergenic regions

TIG-3 cells, respectively (Table 2b). The overlap of newly identified HIF-1 $\alpha$  target alternative promoters with previously characterized transcript models that are present in representative databases is shown in Supplementary Table 4. It is possible there is an unexpectedly large population of the hitherto undiscovered alternative promoters involved in hypoxic response of cells.

**HIF-1 $\alpha$  binding sites in intergenic regions**

The combination of ChIP-Seq and TSS-Seq allowed us to identify HIF-1 $\alpha$  targets even in previously unannotated (so-called "intergenic") regions. Approximately one-third of the HIF-1 $\alpha$  binding sites were located in regions that were >50 kb from the nearest RefSeq genes. For these intergenic binding sites, we searched for TSCs located from 1 kb upstream to 10 kb downstream of the HIF-1 $\alpha$  binding sites and identified 262 and 105 putative HIF-1 $\alpha$  target TSCs in DLD-1 and TIG-3 cells, respectively (Table 2). Twenty-one and 21 binding sites were located in repetitive regions (see also Supplementary Table 5), which suggested that some HIF-1 $\alpha$  target sites might also have arose from repetitive regions, as previously reported for several transcription factors (Tomilin 2008; Polak and Domany 2006) (see Supplementary Fig. 14 for one of these examples). We

also found that the distributions of the distances from HIF-1 $\alpha$  binding sites to TSCs were similar to those determined for the HIF-1 $\alpha$  target RefSeq genes (Supplementary Fig. 15).

We searched the completely sequenced full-length cDNAs that corresponded to these TSCs and found seven overlapping cDNAs from the FLJ (Ota et al. 2004) and MGC (Gerhard et al. 2004) cDNA collections in DLD-1 and TIG-3 cells (Supplementary Table 6a). All of the corresponding full-length cDNAs lacked clear open reading frames. We determined the complete sequences of the overlapping ESTs for an additional three cases and obtained similar results (Supplementary Table 6b). An analysis of the RNA-Seq tags in the polysome fractions also suggested that majority of these intergenic HIF-1 $\alpha$  targets were not translated (Supplementary Fig. 6c). Therefore, the intergenic TSCs of HIF-1 $\alpha$  targets should be used to transcribe hypoxia-responsive non-protein-coding transcripts (Wilusz et al. 2009).

To determine whether these TSCs were precursors of micro-RNAs (He and Hannon 2004), we searched for miRNAs registered in the miRBase (Griffiths-Jones et al. 2006) from 10 kb upstream to 50 kb downstream of the intergenic HIF-1 $\alpha$  binding sites. No miRNAs were located within these regions. Furthermore, we could not detect any